MicroRNA in Human Malignancies

Massimo Negrini is an associate professor in Oncology at the University of Ferrara, where he teaches Molecular Oncology in different graduate and post-graduate programs. He is also director of the Specialization School in Oncology at the University of Ferrara and a biologist executive at the Hospital of Ferrara. He is editor-in-chief of the journal High-Throughput, an international, open access biomedical journal focused on the use of high-throughput technologies (microarray, NGS and other) and serves on the editorial boards of several other international biomedical journals focused on nucleic acids investigation. Prof. Negrini has co-authored more than 248 papers in international peer-reviewed journals. George A. Calin received both his M.D. and Ph.D. degrees at Carol Davila University of Medicine in Bucharest, Romania. Since 2007, he has run an independent research group at the M. D. Anderson Cancer Center in Houston and produced a new advance by linking new classes of non-coding RNAs to cancer. He is presently a Professor in Experimental Therapeutics at MDACC and studies the roles of microRNAs (miRNAs) and other non-coding RNAs in cancer initiation and progression and in immune disorders, as well as the mechanisms of cancer predisposition linked to ncRNAs. Furthermore, he explores the roles of body fluids miRNAs as potential hormones and biomarkers, as well as new RNA therapeutic options for cancer patients. He has co-authored more than 400 papers and over 20 book chapters Carlo M. Croce received his B.S. and M.D. degrees from University of Rome. In 1991, Dr. Croce was recruited as director of Kimmel Cancer Institute/Kimmel Cancer Center, Thomas Jefferson University. From 2004-2018, Dr. Croce served as John W. Wolfe Chair in Human Cancer Genetics, Chairman of the Department of Molecular Virology, Immunology and Medical Genetics, and Director of the Institute of Genetics, The Ohio State University (OSU). He is currently professor with the Department of Cancer Biology and Genetics at OSU. He has published more than 1,000 papers in international journals including Science, Nature, Cell, New Engl J Med, JAMA, and Cancer Cell. His research has yielded 62 issued U.S. patents. Dr. Croce is a member of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, The National Academy of Sciences, the Institute of Medicine, and AACR Academy.

• SECTION 1: miRNAs involvement in basic mechanisms of cancer development1. Overview on miRNA classification, biogenesis, and functions2. microRNA in cancer: overview3. miR-15/16 in human malignancies4. microRNAs and TP53 regulation5. microRNAs involvement in Invasion and metastasis6. microRNAs and metabolism7. microRNAs in inflammation processesSECTION 2: miRNAs methodologies8. Wet-lab methods for miRNA analysis9. Bioinformatics utilities, web resources and integrative strategies for the analysis of miRNA regulatory networks10. Computational Resources for Analysis of miRNA Targetome11. miRNA bioinformatics and pathway analysis SECTION 3: miRNAs involvement in therapeutics / theranostics12. Opportunities of miRNAs in cancer therapeuticsSECTION 4: miRNAs involvement in human cancer: pathophysiology and translational opportunities13. Pathophysiology roles and translational opportunities of miRNAs in acute leukemias14. Pathophysiology roles and translational opportunities of miRNAs in CLL15. Pathophysiology roles and translational opportunities of miRNAs in Lymphoma16. Pathophysiology roles and translational opportunities of miRNAs in Breast cancer17. Pathophysiology roles and translational opportunities of miRNAs in colorectal cancer18. Pathophysiology roles and translational opportunities of miRNAs in Lung cancer19. Pathophysiology roles and translational opportunities of miRNAs in Mesothelioma20. Pathophysiology roles and translational opportunities of miRNAs in Renal cancer21. Pathophysiology roles and translational opportunities of miRNAs in Pancreatic cancer22. Pathophysiology roles and translational opportunities of miRNAs in Prostate cancer23. Pathophysiology roles and translational opportunities of miRNAs in Hepatocarcinoma24. Pathophysiology roles and translational opportunities of miRNAs in Ovarian cancer25. Pathophysiology roles and translational opportunities of miRNAs in Bladder cancer26. Pathophysiology roles and translational opportunities of miRNAs in Cutaneous Melanoma27. Pathophysiology roles and translational opportunities of miRNAs in Brain tumors28. Pathophysiology roles and translational opportunities of miRNAs in Sarcomas